Present and Future Therapeutic Approaches to Barrier Dysfunction.

Autor:	Fortea M; Laboratory for Enteric NeuroScience, Translational Research Center for GastroIntestinal Disorders, University of Leuven, Leuven, Belgium., Albert-Bayo M; Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Barcelona, Spain., Abril-Gil M; Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Barcelona, Spain., Ganda Mall JP; Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Barcelona, Spain.; Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden., Serra-Ruiz X; Department of Gastroenterology, Vall d'Hebron Hospital Universitari, Barcelona, Spain., Henao-Paez A; Department of Gastroenterology, Vall d'Hebron Hospital Universitari, Barcelona, Spain., Expósito E; Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Barcelona, Spain., González-Castro AM; Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Barcelona, Spain., Guagnozzi D; Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Barcelona, Spain.; Department of Gastroenterology, Vall d'Hebron Hospital Universitari, Barcelona, Spain.; Facultad de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERHED), Instituto de Salud Carlos III, Madrid, Spain., Lobo B; Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Barcelona, Spain.; Department of Gastroenterology, Vall d'Hebron Hospital Universitari, Barcelona, Spain.; Facultad de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain., Alonso-Cotoner C; Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Barcelona, Spain.; Department of Gastroenterology, Vall d'Hebron Hospital Universitari, Barcelona, Spain.; Facultad de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERHED), Instituto de Salud Carlos III, Madrid, Spain., Santos J; Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Barcelona, Spain.; Department of Gastroenterology, Vall d'Hebron Hospital Universitari, Barcelona, Spain.; Facultad de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERHED), Instituto de Salud Carlos III, Madrid, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in nutrition [Front Nutr] 2021 Oct 28; Vol. 8, pp. 718093. Date of Electronic Publication: 2021 Oct 28 (Print Publication: 2021).
DOI:	10.3389/fnut.2021.718093
Abstrakt:	There is converging and increasing evidence, but also uncertainty, for the role of abnormal intestinal epithelial barrier function in the origin and development of a growing number of human gastrointestinal and extraintestinal inflammatory disorders, and their related complaints. Despite a vast literature addressing factors and mechanisms underlying changes in intestinal permeability in humans, and its connection to the appearance and severity of clinical symptoms, the ultimate link remains to be established in many cases. Accordingly, there are no directives or clinical guidelines related to the therapeutic management of intestinal permeability disorders that allow health professionals involved in the management of these patients to carry out a consensus treatment based on clinical evidence. Instead, there are multiple pseudoscientific approaches and commercial propaganda scattered on the internet that confuse those affected and health professionals and that often lack scientific rigor. Therefore, in this review we aim to shed light on the different therapeutic options, which include, among others, dietary management, nutraceuticals and medical devices, microbiota and drugs, and epigenetic and exosomes-manipulation, through an objective evaluation of the scientific publications in this field. Advances in the knowledge and management of intestinal permeability will sure enable better options of dealing with this group of common disorders to enhance quality of life of those affected. Competing Interests: CA-C discloses past scientific collaboration with Noventure S.L. JS has served as consultant for Noventure and discloses present and past recent scientific collaborations with Salvat, Norgine, Alfa-Sigma, Cosmo, Adare, Devintecpharma, Pileje and Danone that do not constitute a conflict of interest in developing the content of the present manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Fortea, Albert-Bayo, Abril-Gil, Ganda Mall, Serra-Ruiz, Henao-Paez, Expósito, González-Castro, Guagnozzi, Lobo, Alonso-Cotoner and Santos.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu